AUS
NZ
UK
CA
USA
IND
_02_06_2025_07_05_23_538703.jpg)
_07_03_2026_03_50_21_133108.jpg)
Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology firm specializing in allogeneic CAR T cell therapies, announced that Chief Executive Officer and Managing Director Leslie Chong has resigned immediately due to personal reasons. Having led the company since 2015, Ms. Chong will remain available to assist with the leadership transition. The Board has launched an immediate search for a new CEO as Imugene advances clinical trials for its lead candidate, azer-cel (azercabtagene zapreleucel), an off-the-shelf CD19-targeting cell therapy for blood cancers.
Key Points
- Imugene Limited (ASX:IMU) develops allogeneic CAR T cell therapies for blood cancers at the clinical stage
- CEO and Managing Director Leslie Chong resigns effective immediately after nearly 11 years with the company
- Ms. Chong joined Imugene in 2015 and guided its evolution into a global clinical-stage biotech company
- Executive Chairman Paul Hopper will oversee senior management during the CEO search, which has commenced immediately
- Lead asset azer-cel continues to deliver promising clinical data targeting CD19 in blood cancer trials
Leadership Change at Imugene as CEO Leslie Chong Steps Down
On 27 July 2026, Imugene Limited announced the immediate resignation of CEO and Managing Director Leslie Chong for personal reasons, concluding nearly 11 years of leadership. Since joining in 2015, Ms. Chong has been pivotal in transforming Imugene into a global clinical-stage biotechnology company focused on innovative cancer therapies. Her departure marks a significant leadership transition during a critical phase of clinical development.
Executive Chairman Paul Hopper praised Ms. Chong's key role in establishing Imugene’s presence in the competitive biotech sector. He expressed gratitude for her dedication and noted it was a privilege to collaborate with her over the past decade. Ms. Chong has agreed to remain available to support the transition and provide continuity during the leadership change.
Advancement of Azer-Cel Program Continues Amid CEO Transition
Despite the leadership shift, Imugene remains focused on progressing its lead asset, azer-cel (azercabtagene zapreleucel), an allogeneic CAR T cell therapy targeting CD19 for blood cancers. The company reported encouraging clinical data from ongoing trials, reinforcing confidence in azer-cel’s therapeutic potential. Ms. Chong highlighted in her resignation statement that important clinical milestones, upcoming data releases, and program advancement opportunities remain ahead, underscoring the asset’s strategic importance.
Azer-cel is designed as an off-the-shelf, donor-derived cell therapy, offering manufacturing and accessibility advantages over autologous therapies. Support from clinical trial participants, investigators, and healthcare professionals continues to bolster its development. The positive clinical signals position Imugene prominently within the expanding global CAR T cell therapy market for hematologic malignancies.
Interim Management and CEO Recruitment Process Underway
Following Ms. Chong’s departure, Executive Chairman Paul Hopper will directly oversee senior leadership until a new CEO is appointed. The Board has initiated an immediate search for executive leadership to guide the company through its next clinical and commercial phases. This interim structure ensures management continuity during the transition.
The CEO search is a critical step as the incoming leader will be responsible for advancing key clinical milestones and potential regulatory approvals. The Board’s swift action aims to minimize disruption to ongoing programs. Ms. Chong’s availability to assist during the transition provides valuable continuity to maintain momentum.
Imugene’s Focus on Innovative Cancer Immunotherapies
Imugene Limited operates as a clinical-stage immuno-oncology company developing cell-based cancer therapies. Its focus on allogeneic CAR T cell technology aims to overcome limitations of patient-specific manufacturing inherent in autologous treatments. The company collaborates with international cancer specialists to advance novel therapeutic options that could transform cancer care, particularly for blood cancers where CAR T therapies have proven efficacy.
Imugene envisions its cell therapy platform as a foundational cancer treatment, addressing unmet needs for effective therapies. This strategic positioning aligns with the rapidly evolving global market for cell-based oncology treatments.
Market Potential for Azer-Cel in Blood Cancer Treatment
Azer-cel targets CD19, a validated antigen on B-cell malignancies including lymphoma and leukemia. This mechanism underpins several approved CAR T therapies. Azer-cel’s allogeneic design distinguishes it within the growing off-the-shelf cell therapy segment, offering scalable manufacturing and broader patient access.
The global blood cancer market presents a significant opportunity, with millions affected by hematologic malignancies requiring improved treatments. Encouraging clinical data supports azer-cel’s potential to meet these needs. Upcoming clinical trial results will be pivotal for regulatory submissions and commercialization prospects across multiple regions.
Board Oversight and Governance During Leadership Transition
Imugene’s Board has proactively managed the leadership change by commencing an immediate CEO search and establishing interim governance with Executive Chairman Paul Hopper overseeing senior management. This approach ensures strategic focus and operational stability during the transition period.
The Board values Ms. Chong’s willingness to remain engaged during the handover, balancing fresh leadership with institutional knowledge. This succession planning underscores Imugene’s commitment to advancing clinical programs and sustaining strategic momentum despite executive changes.
Clinical Collaborations and Patient Engagement
Imugene’s development of azer-cel depends on partnerships with clinical investigators, physicians, healthcare professionals, and patient participants. Ms. Chong acknowledged the vital role of these stakeholders in enabling the generation of clinical evidence required for regulatory progress and market adoption.
The company’s clinical trial infrastructure supports rigorous evaluation of azer-cel’s safety and efficacy in blood cancer patients. Maintaining these relationships during the leadership transition is essential to preserving trial progress and achieving upcoming clinical milestones.
Growth Drivers in the Global Cell Therapy Market
Imugene operates within the expanding cell and gene therapy sector, propelled by regulatory approvals, clinical validation, and increased investment. CAR T therapies, including azer-cel’s class, have achieved commercial success and represent a rapidly growing market segment. The shift toward allogeneic, off-the-shelf therapies addresses manufacturing scalability and accessibility challenges faced by autologous approaches.
Global biotech and pharmaceutical companies are investing heavily in cell therapy platforms to overcome production and distribution constraints. Imugene’s allogeneic strategy positions it well amid these sector trends. Upcoming clinical milestones and data releases for azer-cel will be crucial in defining the company’s competitive standing and market capture potential.
Investor Outlook and Upcoming Milestones
Investors will closely monitor the CEO search timeline and appointment, which will signal Imugene’s future strategic direction. Additionally, the progression of azer-cel’s clinical trials, with key milestones and data readouts highlighted by Ms. Chong, will significantly impact investor sentiment and valuation.
The interim governance under Executive Chairman Paul Hopper ensures operational continuity. Ms. Chong’s availability for consultation may aid in preserving institutional knowledge. Ultimately, the success of this leadership transition depends on securing a CEO capable of advancing Imugene’s clinical pipeline and capitalizing on azer-cel’s promising data. Market participants will scrutinize clinical timelines and outcomes to assess progress during this period.
